TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02286622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite 21-desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite 21-desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone
Study: NCT00983827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aquatic treadmill training
Description: HydroWorx aquatic therapy pool with an underwater, integrated and adjustable speed treadmill
Study: NCT03132155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 337
Description: 6-{(1R)-1-\[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)\[1,2,4\]triazolo\[4,3-a\]pyridin-3-yl\]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
Study: NCT03042091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neomycin
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Hydrochloride
Description: Given orally

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo colorectal resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo colorectal resection
Study: NCT00131495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone (transdermal patches)
Description: Testosterone patch (300mcg/day, changed twice a week for one year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: placebo patch changed twice a week for one year
Study: NCT01442142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAAT: Appetite Awareness
Description: Participants in this Children's Appetite Awareness Training (CAAT) group learn to get in touch with the internal cues of hunger - aka the hunger meter - and practice skills to get back in touch with these internal cues of true hunger and fullness. Sessions occur once a week for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRST: Volcravo
Description: Participants in this Cue Reactivity and Sensitivity Training (CRST) group learn about how external cues can affect when and how much we eat (aka volcravo - the craving volcano). Over 8 weekly sessions, they practice skills to ride out the cravings external cues can cause.
Study: NCT01142024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: NS 500ml + Glutathione 1.8g intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: NS 500ml intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
Study: NCT04350060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retro-fitted room with technological enhancements
Description: Reconstructing and retrofitting a currently existing memory care room at Samaritan Bethany Arbor Terrace Senior Living with integrated technologies specifically to accommodate the needs of persons with dementia to enhance sensory stimulation in sight, sound and sleep.
Study: NCT03974204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment
Description: At the initial diagnostic assessment, 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected in order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are Lack of evidence according to EANO-ESMO classification
Description: 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~* When suspected metastatic meningitis symptoms arise and~* at least 3 months after the initial diagnostic assessment, In order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are confirmed, probable or possible, leading to leptomeningeal metastase specific treatment
Description: 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~* 1 month after the beginning of the specific treatment,~* 3 months after the beginning of the specific treatment. Cerebrospinal fluid will be collected during a lumbar puncture aiming to assess treatment response or at intrathecal injection of treatment.
Study: NCT02698371

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: G1-Control: Futurabond®DC-SE (FBDC_SE)
Description: Futurabond®DC (FBDC) adhesive by self-etch (SE) mode bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: G2-Control: Futurabond®DC_SE_EE
Description: Futurabond®DC adhesive by self-etch mode with selective enamel etching (FBDC-SE-EE) bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.

Intervention type: DEVICE
Group type: OTHER
Intervention: G3: Futurabond® U - ER (FBU_ER)
Description: FuturabondU® (FBU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.

Intervention type: DEVICE
Group type: OTHER
Intervention: G4: Futurabond® U - SE (FBU_SE)
Description: FuturabondU® (FBU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.

Intervention type: DEVICE
Group type: OTHER
Intervention: G5: Adhese® Universal - ER (ADU_ER)
Description: Adhese®Universal (ADU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.

Intervention type: DEVICE
Group type: OTHER
Intervention: G6: Adhese® Universal - SE (ADU_SE)
Description: Adhese®Universal (ADU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
Study: NCT03139799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental - Puzzle Video Game Intervention
Description: The psychological intervention consists of two custom-made versions of popular commercial casual puzzle video games (Flow Free, Big Duck Games LCC; Bejeweled, PopCap Games). The puzzle games are delivered on tablet-computers computer (12.9-inch tablet computer iPad Pro, Apple Inc., Cupertino, CA, USA).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental - Puzzle Video Game Intervention
Description: The psychological intervention consists of two custom-made versions of popular commercial casual puzzle video games (Flow Free, Big Duck Games LCC; Bejeweled, PopCap Games). The puzzle games are delivered on tablet-computers computer (12.9-inch tablet computer iPad Pro, Apple Inc., Cupertino, CA, USA).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control - Tablet Newspaper Reading Intervention
Description: The control intervention uses a newspaper/ magazine reading task that will be delivered to participants using the same device (iPad Pro) as in the experimental intervention. The newspaper/ magazine reading task will be running on the built-in Apple Newsstand application. Participants will be offered subscriptions for two newspapers and/or magazines that they are instructed to read following the same regime as in the experimental condition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control - Tablet Newspaper Reading Intervention
Description: The control intervention uses a newspaper/ magazine reading task that will be delivered to participants using the same device (iPad Pro) as in the experimental intervention. The newspaper/ magazine reading task will be running on the built-in Apple Newsstand application. Participants will be offered subscriptions for two newspapers and/or magazines that they are instructed to read following the same regime as in the experimental condition.
Study: NCT00267150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Description: Experimental
Study: NCT01442142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined CAAT and CRST program
Description: Participants meet weekly for 14 weeks to learn about both Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST) - i.e. appetite awareness and external cues that affect food intake.
Study: NCT04087824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI assisted recognition of colonic segments
Description: After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. The whole withdrawal process is monitored by AI associated recognition system. Key colonic segments include ileocecal valve, ascending colon, transverse colon, descending colon, sigmoid colon and rectum. When typical anatomic sites are detected, the AI device will automatically captured relevant images and report the name of each segment on the screen. The operating endoscopy expert will give the final answer and judge the performance of AI, which is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
Study: NCT03928847

Intervention type: DRUG
Group type: OTHER
Intervention: Epigallocatechin-3-gallate (EGCG)
Description: Epigallocatechin-3-gallate (EGCG) capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epigallocatechin-3-gallate (EGCG)
Description: Epigallocatechin-3-gallate (EGCG) capsules
Study: NCT06523036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined chiropractic care and Tai Chi
Description: Chiropractic will be personalized to the patients clinical needs within the scope of chiropractic practice in the Commonwealth of Massachusetts including: posture correction/spinal stabilization exercises; soft tissue relaxation techniques; spinal manipulation/mobilization; breathing and relaxation techniques; stretches, self-care; ergonomic modifications; bracing and supports. Chiropractic will be administered by one of two chiropractors at the Osher Clinical Center. Tai Chi will take place at one of two schools used in prior NIH funded trials.
Study: NCT00942292

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipidem- fish oil emulsion BBraun UK
Study: NCT03700814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Description: Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.
Study: NCT03725007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib is administered as an oral solution or tablet as described in protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib is administered as an oral solution or tablet as described in protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib is administered as an oral solution or tablet as described in protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib is administered as an oral solution or tablet as described in protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Upadacitinib is administered as an oral solution or tablet as described in protocol.
Study: NCT03410342

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LFV
Description: 1 apple/banana/small bunch of grapes per day plus 1 portion of carrot/pepper/tomato per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFV
Description: 4 portions of fruits (apples, bananas, grapes, pears) plus 4 portions of vegetables (carrots, cucumber, sweet peppers, tomatoes), of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CC
Description: 4 portions of citrus fruits (clementines, grapefruits, lemons, oranges) plus 4 portions of cruciferous vegetables (broccoli, brussels sprouts, cauliflower, kale, savoy cabbage) per day.
Study: NCT03011255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peptide specific CTL
Description: Radiation: RT to 60 Gy, 5 x per week，for 6 weeks Biological: Peptide specific CTL Peptide specific CTL will be administered by intravenous injection on day 28 of radiation.
Study: NCT03147794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyndMove
Description: A new technology system called MyndMove has been developed by MyndTec Inc. (Missisauga Canada) to administer FES. The purpose of this technology is to improve voluntary upper limb (hand and arm) function (i.e. reaching and grasping) for patients with hemiparesis as a results of stroke or spinal cord injury (7). It is a non-invasive application that delivers electrical stimulation to the affected limb transcutaneously. MyndMove has been licensed by Health Canada and is indicated as a functional electrical stimulator for improvement of arm and hand function and active range of motion in patients with hemiplegia due to stroke or upper limb paralysis due to C3-C7 spinal cord injury.
Study: NCT01431118

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: specific dragon boating training intervention
Description: male athletes of the german national dragon boat team performing three specific training units at one day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: specific dragon boat intervention
Description: women athletes of the german national dragon boat team performing two specific training units and one weight lifting test at one day
Study: NCT01750424

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting
Study: NCT01750424

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: Subjects in this arm will only be followed up and have no procedure performed.
Study: NCT03790839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin (Januvia® 100 mg tablets for oral administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzagliatin
Description: Glucokinase activator currently under development
Study: NCT03727503

Intervention type: OTHER
Group type: OTHER
Intervention: PPV from the capstesia
Description: we will challenge the application by doing 2 maneuvers: the first one is to increase the PEEP level from 5 to 15 cmH2O and the second one is the infusion of a mini-fluid challenge (100 ml) followed by the other 400 ml.
Study: NCT02764905

Intervention type: BEHAVIORAL
Intervention: intensive cognitive physical rehabilitation program
Description: include 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies.
Study: NCT01344980

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stainless steel suture
Description: Stainless steel suture material will be used (size 3-0) in an MGH repair technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polypropylene suture
Description: Polypropylene suture (size 3-0) will be used in a double-locking loop repair technique

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aggressive early active range of motion rehabilitation
Description: Patients undergoing this form of rehabilitation will have their splints discontinued at 4 weeks and ideally will be back at work at normal duties by 6 weeks. This rehabilitation uses more movement at a faster progression than other early active range of motion protocols.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early active range of motion rehabilitation
Description: Patients undergoing this form of rehabilitation will have their splints discontinued at 6 weeks and ideally will be back at work at normal duties by 10-12 weeks. This rehabilitation uses less movement at a slower progression than the early AROM rehabilitation protocol specified in the experimental group
Study: NCT02203799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy (POIT)
Description: The peanut protein is ingested in the form of peanut flour. Peanut flour will be given in small pre-measured soufflé cups containing the amount of peanut flour that needs to be eaten for one dose. One dose will be taken per day. Dosage of the peanut flour will begin with 1.8 mg of peanut protein during the initial visit or the lowest tolerated dose on initial challenge and increased every 2 during the build-up phase until the maintenance dose of peanut protein (3900 mg) is reached.
Study: NCT02671266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.
Study: NCT01881230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel 125 mg/m\^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel 125 mg/m\^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
Study: NCT00681109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% IL-1Ra
Description: 2.5% custom made topical IL-1Ra three times a day in both eyes for three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: custom eye drop to be applied three times a day in both eyes for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% IL-1Ra
Description: 5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months
Study: NCT02504801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: To test the hypothesis that nebulizer Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD. Compare post-operation pulmonary complication incidence in two arms among primary lung cancer patients with COPD required single lobectomy from 3 days before operation to 7 days after operation.
Study: NCT00701415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase beta
Description: Powder for concentrate for solution for infusion 1.0 mg/kg/4 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase beta
Description: Powder for concentrate for solution for infusion 0.5 mg/kg/2 weeks
Study: NCT02067494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Soft Tissue Release
Description: Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio taping treatment
Description: Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain.
Study: NCT02261233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Up to 4 sessions of osteopathic manipulative treatment (once per week)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Up to 4 sessions of osteopathic manipulative treatment (once per week)
Study: NCT01228292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: dose 5-10 IU/kg/hrs adaptations of infusion rate upon APTT measurements during hemodialysis